Device Groups Propose "Two-Tier" PS As Least Burdensome Alternative
This article was originally published in The Gray Sheet
Executive Summary
FDA should require device manufacturers to conduct targeted postmarket studies only if specific problems arise during routine monitoring, the American Society for Quality says in Nov. 27 comments to the agency on a proposed rule for postmarket surveillance (PS).
You may also be interested in...
PTCA Catheter Downclassification Carries Unresolved Safety Issues - Panel
Postmarket surveillance requirements should be part of any decision to downclassify percutaneous transluminal coronary angioplasty (PTCA) balloon catheters from Class III to Class II, according to FDA's Circulatory System Devices Panel.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.